---
title: "Varegacestat (AL102) in Desmoid tumors: Radiotherapy"
description: "Formulary evidence on Varegacestat (AL102, BMS-986115) in Desmoid tumors: Radiotherapy. Topics: Moderate-dose definitive radiotherapy when surgery is not an option; Radiotherapy combined with or compared with surgery; Dose of 56 Gy in 28 fractions and post-operative radiotherapy; Radiotherapy dose, local control, and late effects; 6 further topics. 10 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description/radiotherapy"
published: "2026-11-18T22:42:04-05:00"
modified: "2026-11-18T22:42:04-05:00"
---

# Varegacestat (AL102) in Desmoid tumors: Radiotherapy

<a id="heading-2.2.2.1.3"></a>

## 2.2.2.1.3 Radiotherapy

<a id="topic-2.2.2.1.3-1"></a>

### Moderate-dose definitive radiotherapy when surgery is not an option

> “When surgery is not an option and active management is required, moderate dose definitive radiotherapy has also been shown to provide adequate local control in a majority of progressive patients and could be considered if medical therapies are not available or not active.”
> “More recently, moderate dose definitive radiotherapy has been employed as an alternative to surgery for symptomatic/growing tumours located at critical sites such as head & neck, scapular girdle, etc.”
> “For head & neck/intrathoracic DT, medical therapy is generally considered the first line option. However, in selected conditions (elder age, patient intolerance/preference, comorbidities, lesion growing rapidly and threatening vital organs, etc.) radiotherapy is a reasonable and effective first line alternative.”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

<a id="topic-2.2.2.1.3-2"></a>

### Radiotherapy combined with or compared with surgery

> “While some reduction in the anticipated absolute risk of recurrence after surgery has been observed with the addition of radiotherapy (37% versus 25%), this reduction is not statistically significant (RR 0.69, 95% CI 0.41–1.17).”
> “The level of evidence for adjuvant radiotherapy is low and this strategy is not devoid of risk in this young patient population (radiation-induced sarcoma).”
> “the anticipated absolute risk of progressive disease after radiotherapy alone is 19% versus 29% after surgery alone, however, not being statistically significant (RR 0.65, 95% CI 0.35–1.22).”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

<a id="topic-2.2.2.1.3-3"></a>

### Dose of 56 Gy in 28 fractions and post-operative radiotherapy

> “Radiotherapy to a dose of 56 Gy in 28 once-daily fractions of 2 Gy has been shown to provide adequate local control in the majority of progressive patients (III, A)”
> “Post-operative radiation has not demonstrated a conclusive benefit after first surgery regardless of resection margins.”

Source: [Kasper et al. (2017b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5834048/)

<a id="topic-2.2.2.1.3-4"></a>

### Radiotherapy dose, local control, and late effects

> “Radiotherapy is an effective treatment option, especially if patients are symptomatic and progressing.”
> “A dose of 50-56 Gy alone or in combination with surgery in patients with incomplete resection can achieve adequate local control at 5 years in 70–80% of patients with unresectable tumors or following incomplete resection.”
> “Post-operative RT after complete surgical resection is not typically recommended in the adjuvant setting.”
> “For young adults, RT should be discussed individually with consideration of its late toxic effects and risk of secondary malignant neoplasms.”

Source: [Alberta Health Services clinical practice guideline SAR-004 (2025)](https://www.ahs.ca/assets/info/hp/cancer/if-hp-cancer-guide-sar004-desmoid.pdf)

<a id="topic-2.2.2.1.3-5"></a>

### EORTC 62991-22998 multicenter prospective phase II trial: local control and response

> “To determine the activity of radiotherapy in patients with inoperable desmoid-type fibromatosis (DF) a multicenter prospective phase II trial was carried out.”
> “(EORTC 62991-22998)”
> “Patients with inoperable progressive disease of primary, recurrent or incompletely resected lesions received a dose of 56 Gy in 28 fractions.”
> “Forty-four patients (27 F/17 M) were enrolled from 2001 to 2008. Median age was 39.5 years.”
> “Median follow-up was 4.8 years. The 3-year local control rate was 81.5% (90% one-sided confidence interval 74% to 100%). Best overall response during the first 3 years was complete response (CR) 6 (13.6%), partial response (PR) 16 (36.4%), stable disease 18 (40.9%), progressive disease 3 (6.8%) and nonassessable 1 (2.3%).”
> “Response after radiation therapy is slow with continuing regression seen even after 3 years.”

Source: [Keus et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23868907/)

<a id="topic-2.2.2.1.3-6"></a>

### EORTC 62991-22998 multicenter prospective phase II trial: acute and late toxicity

> “Acute grade 3 side-effects were limited to skin, mucosal membranes and pain. Late toxic effect consisted of mild edema in 10 patients.”

Source: [Keus et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23868907/)

<a id="topic-2.2.2.1.3-7"></a>

### Review of six studies of definitive radiotherapy for unresectable tumors: local control and late complications

> “Among 218 identified studies, only 6 were finally included in this review. Local control was achieved in 253 of 317 patients with unresectable or unresected tumors who underwent definitive radiation therapy (the crude rate of local control was 79.8%).”
> “Frequent late complications of radiation therapy included fibrosis/contracture/joint stiffness, skin disorders, lymphedema and pain. Six patients developed secondary malignancies in the radiation field.”

Source: [Matsunobu et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32115624/)

<a id="topic-2.2.2.1.3-8"></a>

### Adjuvant radiotherapy after resection with negative or positive margins

> “Adjuvant radiotherapy after surgery with negative margins had no detectable benefit on recurrence. In contrast, after incomplete surgical resection, adjuvant radiotherapy improved recurrence rates both in patients with primary tumours (RR 1·54, 1·05 to 2·27) and in those with recurrent DF (RR 1·60, 1·12 to 2·28).”

Source: [Janssen et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28199014/)

<a id="topic-2.2.2.1.3-9"></a>

### Adjuvant radiation in a surgical series

> “In our series, there was no improvement in outcomes in patients who had received radiation therapy during the course of their treatment (5-year LRFS 68% vs 72% without radiation; Figure 3A).”
> “LRFS among patients with extremity tumors was 71% with radiation vs. 56% without (p=0.029).”

Source: [Crago et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4096320/)

<a id="topic-2.2.2.1.3-10"></a>

### Criterion of tumors not amenable to surgery or radiotherapy

> “C) The desmoid tumors are not amenable to surgery or radiotherapy; AND”

Source: [Express Scripts nirogacestat criteria (2023)](https://express-scripts.com/sites/default/files/policies/Oncology%20-%20Ogsiveo%20PA%20Policy.pdf)

## Related pages
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors.md)
- [Varegacestat (AL102) in Desmoid tumors: Terms and abbreviations](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations.md)
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary.md)
- [Varegacestat (AL102) in Desmoid tumors: Product information and disease description](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description.md)
- [Varegacestat (AL102) in Desmoid tumors: Clinical evidence](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence.md)
- [Varegacestat (AL102) in Desmoid tumors: Economic information and modeling report](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics.md)
- [Varegacestat (AL102) in Desmoid tumors: References](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references.md)
